Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis
Genes and Immunity, 08/14/09
Heckmann JM et al. – Findings suggest that at critical periods during autoimmune MG, this SNP may result in inadequate DAF upregulation with consequent complement–mediated EOM damage. Susceptible individuals may benefit from anti–complement therapy in addition to immunosuppression.
Associate Professor JM Heckmann, 08/17/09
| Extraocular muscles (EOMs) are commonly involved in active myasthenia gravis (MG) and most myasthenics develop fatiguable weakness of one or more EOMs, most likely at disease onset. If MG remains confined to the EOMs for a 2-year period and does not generalize, it is referred to as "ocular MG". In this report we investigated a different group of MG subjects that developed severe EOM pareses (i.e. non-fatiguable); most affected subjects developed this complication after generalized MG was diagnosed and whilst receiving standard immunosuppressive treatment. Further, in these subjects the ophthalmoparesis and ptosis did not respond to increasing prenisone treatment. Our current study results suggest that individuals who have MG and the SNP in the regulatory region of the DAF gene, may be at risk of indadequate DAF upregulation at critical periods during MG, which in turn may require additional anti-complement therapy to prevent EOM damage. |
Today in Neurologic/Ophthalmic...keeping you current
Receive free subspecialty "5-minute updates" via email
Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms
Therapeutic Advances in Neurological Disorders, 11/10/09
The management of allergic eye diseases in primary eye care
Contact Lens and Anterior Eye, 11/03/09
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Archives of Neurology, 11/19/09
Today in Rheumatic/Autoimmune...keeping you current
Receive free subspecialty "5-minute updates" via email
Vaccination, atherosclerosis and systemic lupus erythematosus
Lupus, 11/05/09
Update in treatment options for psoriatic arthritis
Expert Review of Clinical Immunology, 11/23/09
Safety of vaccination of patients with systemic lupus erythematosus
Lupus, 11/04/09
Sponsor
Article Search
Sponsor


See Latest Articles


